
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a vaccine called TroVax for the following cancers that have come back after initial treatment
Doctors initially treat these cancers with surgery and chemotherapy. After treatment, you may have blood tests to look for a marker called . Having an increased amount of CA125 in your blood may mean that your cancer has come back. But you can have an increased level of CA125, without any other signs or symptoms of your cancer having come back. If this happens, your doctor may not want to start chemotherapy until you have signs or symptoms.
TroVax helps the immune system to recognise and attack cancer cells. Many cancer cells carry a protein called 5T4. In this trial, researchers want to find out if TroVax helps the immune system to recognise 5T4 and attack cancer cells that carry this protein.
The aim of this trial is to find out if giving TroVax after a rise in CA125 can slow the growth of cancer and delay the start of chemotherapy.
You may be able to enter this trial if
You cannot enter this trial if
This is a phase 2 trial. It will recruit about 100 people.
This was a randomised trial. The people who agreed to take part between 2013 and 2016 were put into treatment groups by a computer. Neither they nor their doctor decided which group they were in. And neither knew which group they were in. This was a double blind trial. Half the people had TroVax. The other half had a dummy drug (placebo).
The researchers now have enough people in the placebo group. Everyone taking part now will have TroVax.
You have TroVax or the dummy drug as an injection into the muscle at the top of your arm. On each visit the opposite arm is used from the time before. You have a total of injections over 25 weeks (about 6 months). You continue treatment as long as it is helping you and the side effects aren’t too bad.
The trial team will ask you to fill out a questionnaire
The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
If you agree to take part in this study, the researchers will ask for extra blood samples during treatment and a sample of your cancer that was removed when you had surgery.
You see the doctor to have some tests before taking part in this trial. These test include
The treatment lasts about 6 months. During this time, you go to the hospital at least 8 times. You have regular blood tests and 2 more scans.
After treatment you see the doctor after
TroVax is a new drug and there may be side effects we don’t know about yet. The possible side effects include
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Agnieszka Michael
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Oxford Biomedica
University College London (UCL)
This is Cancer Research UK trial number CRUKE/11/059.
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.